Review Article
Volume 11 Issue 2 - 2020
Ocular Involvement in Behcet’s Disease: An Overview
Faten Frikha*, Mouna Snoussi, Raida Ben Salah and Zouhir Bahloul
Department of Internal Medicine, Hedi Chaker Hospital, Medical University School of Sfax, Tunisia
*Corresponding Author: Faten Frikha, Department of Internal Medicine, Hedi Chaker University Hospital, Medical University School of Sfax, Tunisia.
Received: September 23, 2019; Published: January 08, 2020


Ocular involvement in Behçet’s disease is frequent and may be associated with a poor functional prognosis. It can be inaugural in 20% of the cases or may develop 2 to 3 years after the beginning of the disease. Uveitis is the most common ocular manifestation and may be anterior, intermediate, posterior or panuveitis. The main goals in the management of ocular involvement are rapid suppression of intraocular inflammation, preservation of vision, and prevention of recurrences. The treatment is based on the use of systemic glucocorticosteroids and immunosuppressive agents. Recent developments like biological agents in the treatment of ocular Behçet’s disease are promising with a rapid effect and high remission rates.

Keywords: Behçet’s Disease; Iridocyclitis; Retinal Vasculitis; Immunosuppressants; Biological Agents


  1. International Study Group for Behçet’s Disease. “Criteria for diagnosis of Behcet’s disease”. Lancet 335 (1990): 1078-10804.
  2. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). “The international criteria for Behc¸et’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria”. Journal of the European Academy of Dermatology and Venereology 28.3 (2014): 338-347. 
  3. Leccese P and Alpsoy E. “Behçet's Disease: An Overview of Etiopathogenesis”. Frontiers in Immunology 10 (2019): 1067. 
  4. Kitaichi N., et al. “Ocular features of Behçet’s disease: An international collaborative study”. British Journal of Ophthalmology 91.12 (2007): 1579-1582.
  5. Hatemi G., et al. “Behçet’s syndrome: a critical digest of the 2014-2015 literature”. Clinical and Experimental Rheumatology 33.94 (2015): S3-S14.
  6. Tugal-Tutkun I., et al. “Uveitis in Behcet disease: An analysis of 880 patients”. American Journal of Ophthalmology 138 (2004): 373-380.
  7. Thomas W., et al. “An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review”. Orphanet Journal of Rare Diseases 12 (2017): 130.
  8. Namba K., et al. “A major review: Current aspects of ocular Behçet’s disease in Japan”. Ocular Immunology and Inflammation 23 (2015): 1-23.
  9. Tugal-Tutkun I., et al. “Review for diagnostics of the year: Multimodal imaging in Behçet uveitis”. Ocular Immunology and Inflammation 25.1 (2017): 7-19.
  10. Oray M., et al. “Nonglaucomatous localized retinal nerve fiber layer defects in Behçet uveitis”. American Journal of Ophthalmology 159.3 (2015): 475-481.
  11. Horie Y., et al. “HLA-B51 carriers are susceptible to ocular symptoms of Behçet disease and the association between the two becomes stronger towards the east along the Silk Road: A literature survey”. Ocular Immunology and Inflammation 25 .1 (2017): 37-40.
  12. Evereklioglu C. “Ocular Behçet disease: current therapeutic approaches”. Current Opinion in Ophthalmology. 22.6 (2011): 508-516.
  13. Tuncer S., et al. “Results of intravitreal triamcinolone acetonide IVTA. injection for the treatment of panuveitis attacks in patients with Behçet disease”. Journal of Ocular Pharmacology and Therapeutics. 23 (2007): 395.
  14. Nussenblatt RB and Palestine AG. “Cyclosporine: immunology, pharmacology and therapeutic uses”. Survey of Ophthalmology 31 (1986): 159-169.
  15. Saadoun D., et al. “Azathioprine in severe uveitis of Behçet’s disease”. Arthritis Care and Research 62 (2010): 1733-1738.
  16. Larkin G and Lightman S. “Mycophenolate mofetil: A useful immunosuppressive in inflammatory eye diseases”. Ophthalmology 106 (1999): 370-374.
  17. Gul A. “Behçet’s disease: an update on the pathogenesis”. Clinical and Experimental Rheumatology 19.24 (2001): S6-S12. 
  18. Yamashita N., et al. “Role of gammadelta T lymphocytes in the development of Behçet’s disease”. Clinical and Experimental Immunology 107 (1997): 241-247.
  19. Levy-Clarke G., et al. “Expert panel recommendations for the use of anti-tumour necrosis factor biologic agents in patients with ocular inflammatory disorders”. Ophthalmology 121.3 (2014): 785-796.
  20. Suhler EB., et al. “A prospective trial of Infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes”. Archives of Ophthalmology 123.7 (2005): 903-912. 
  21. Hamza MM., et al. “Intravitreal Infliximab in refractory Uveitis in Behçet’s disease: a safety and efficacy clinical study”. Retina 36.12 (2016): 2399-2408.
  22. Markomichelakis N., et al. “A single Infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study”. Rheumatology 50.3 (2011): 593-597.
  23. Atsuko Katsuyama., et al. “Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behçet’s disease”. Clinical Ophthalmology 13 (2019): 521-527.
  24. Hatemi G., et al. “EULAR recommendations for the management of Behcet disease”. Annals of the Rheumatic Diseases 67 (2008): 1656-1662.
  25. Olivieri I., et al. “Efficacy of Adalimumab in patients with Behçet's disease unsuccessfully treated with Infliximab”. Clinical and Experimental Rheumatology 29 (2011): S54. 67. 
  26. Bawazeer A., et al. “Clinical experience with Adalimumab in the treatment of ocular Behçet disease”. Ocular Immunology and Inflammation 18.3 (2010): 226-232.
  27. Sfikakis P. “Behçet’s disease: a new target for anti-tumour necrosis factor treatment”. Annals of the Rheumatic Diseases 61.2 (2002): ii51-53.
  28. Smith MR. “Rituximab. monoclonal anti-CD20 antibody: mechanisms of action and resistance”. Oncogene 22.47 (2003): 7359-7377. 
  29. Kneitz C., et al. “Effective B cell depletion with rituximab in treatment of autoimmune diseases”. Journal Immunobiology. 206.5 (2002): 519-527.
  30. Davatchi F., et al. “Rituximab in intractable ocular lesions of Behçet’s disease randomized single-blind control study pilot study”. International Journal of Rheumatic Diseases 13 (2010): 246-252.
  31. Calvo-Río V., et al. “Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review”. Clinical and Experimental Rheumatology 32 84 (2014): S54-57.
  32. Cantarini L., et al. “Anakinra treatment in drug-resistant Behçet’s disease: a case series”. Clinical Rheumatology 34 (2015): 1293-1301.
  33. Blech M., et al. “One target two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β”. Journal of Molecular Biology 425.1 (2013): 94-111.
  34. Hasanreisoglu M., et al. “Interferon alpha-2a therapy in patients with refractory Behçet uveitis”. Ocular Immunology and Inflammation 25.1 (2017): 71-75.
  35. Hatemi G., et al. “2018 update of the EULAR recommendations for the management of Behçet's syndrome”. Annals of the Rheumatic Diseases 77.6 (2018): 808-818. 
  36. Kacmaz RO., et al. “Ocular inflammation in Behçet disease: Incidence of ocular complications and of loss of visual acuity”. American Journal of Ophthalmology 146 (2008): 828-836.
Citation: Faten Frikha., et al. “Ocular Involvement in Behcet’s Disease: An Overview”. EC Ophthalmology 11.2 (2020): 01-08

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

September Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the September issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for October Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the November issue of respective journals. Submissions are accepted on/before October 07, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to